ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ADMA BIOLOGICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$11.07+0.39 (+3.65%)
Close on Oct 19, 2026
- Market cap
- $2.55B
- P/E (TTM)
- 15.8
- Dividend yield
- –
ADMA BIOLOGICS, INC. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADMA BioManufacturing [Member] | $494.71M | $493.03M | $493.00M | $481.64M | $465.17M | $449.41M | $415.81M | $377.85M | $326.70M | $280.27M | $249.74M | $224.85M | 96.6% | +6.4% |
| Plasma Collection Centers [Member] | $17.42M | $16.70M | $17.03M | $6.77M | $8.86M | $9.83M | $10.51M | $4.82M | $3.41M | $2.76M | $8.33M | $9.30M | 3.4% | +96.6% |
| Corporate [Member] | – | – | – | – | – | – | – | $144.00K | $144.00K | $144.00K | $143.00K | $143.88K | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADMA BioManufacturing [Member] | – | – | – | – | – | – | – | $144.70M | $111.37M | $70.75M | $47.53M | $31.88M | – |
| Plasma Collection Centers [Member] | – | – | – | – | – | – | – | -$5.07M | -$3.99M | -$4.16M | -$4.05M | -$8.42M | – |
| Corporate [Member] | – | – | – | – | – | – | – | -$24.74M | -$23.44M | -$22.32M | -$21.85M | -$22.12M | – |
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $508.10M | $506.76M | $504.07M | $481.38M | $462.15M | $442.89M | $410.15M | $366.43M | $316.30M | $270.18M | $244.88M | $223.90M | 99.2% | +9.9% |
| International [Member] | $4.18M | $3.10M | $6.11M | $7.18M | $12.03M | $16.49M | $16.31M | $16.38M | $13.95M | $13.00M | $13.33M | $10.39M | 0.8% | -65.3% |
From the segment and revenue-disaggregation notes of Adma Biologics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.